Article

PHACE without Face? Infantile Hemangiomas of the Upper Body Region with Minimal or Absent Facial Hemangiomas and Associated Structural Malformations

University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Pediatric Dermatology (Impact Factor: 1.52). 03/2011; 28(3):235-41. DOI: 10.1111/j.1525-1470.2011.01407.x
Source: PubMed

ABSTRACT Infantile hemangiomas can be associated with congenital anomalies such as PHACE syndrome with facial hemangiomas and genitourinary and spinal anomalies in the setting of lower body hemangiomas. We describe five infants in whom segmental hemangiomas involving the upper torso and extremities with absent or small facial hemangiomas were associated with structural anomalies similar to those reported with PHACE syndrome, including three with structural arterial anomalies of the subclavian arteries, three with aortic arch anomalies (right sided or narrowed arch), two with congenital heart disease (atrial septal defect and ventricular septal defect; tetralogy of Fallot), one with a retinal scar, and one with a sternal defect (scar). Two of five had small facial hemangiomas of the lower lip, but none had large segmental hemangiomas of the face. Three of five would have met diagnostic criteria for PHACE but lacked a facial hemangioma of 5 cm in diameter or greater. Patients with segmental arm and thorax hemangiomas may have associated structural abnormalities with overlapping features of PHACE, suggesting that a similar syndrome can occur in this clinical setting.

0 Followers
 · 
72 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Propranolol has replaced corticosteroids as preferred first-line therapy for the management of infantile hemangiomas (IH). The topical β-blocker timolol is now an alternative to oral propranolol and watchful waiting for smaller IH. Research in the last decade has provided evidence-based data about natural history, epidemiology, and syndromes associated with IH. The most pressing issue for the clinician treating children with IH is to understand current data to develop an individualized risk stratification for each patient and determine the likelihood of complications and need for treatment. This article emphasizes the nuances of complicated clinical presentations and current treatment recommendations.
    Pediatric Clinics of North America 04/2014; 61(2):383-402. DOI:10.1016/j.pcl.2013.11.010 · 2.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In PHACES syndrome a facial infantile hemangiomas (IH) is associated with extracutaneous manifestations involving the central nervous system, heart, blood vessels of head and neck, eye and sternum. Recently, an IH of the upper trunk was reported in association with extravcutaneous manifestations reminiscent of PHACES syndrome. Here we report a case of a 7-month-old girl with segmental hemangioma involving the upper trunk and limb. It was associated with structural anomalies similar to those reported in PHACES syndrome, including congenital heart disease, arterial abnormalities and a sternal defect; moreover there was a late-onset small hemangioma of the face.
    European Journal of Pediatric Dermatology 06/2014; 2014(24(2)):78-81.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite their high incidence, most infantile hemangiomas (IH) do not require treatment as they regress spontaneously and most do not leave significant sequelae. For the subset of hemangiomas that require treatment, indications for intervention can be divided into three main categories: ulceration, disfigurement, and impairment of function or vital structures. In addition, certain IH have a risk of associated structural anomalies. Given the wide heterogeneity of hemangiomas deciding which hemangiomas need intervention and when to intervene requires a detailed knowledge of natural history and clinical indicators of increased risk. This article is protected by copyright. All rights reserved.
    British Journal of Dermatology 05/2013; 169(1). DOI:10.1111/bjd.12436 · 4.10 Impact Factor